STERIS stock trades at EUR 197.65 with USD 21.6 billion value

Published on 10/20/2026 at 13:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

STERIS agreed to buy Xodus for USD 2.10 billion on October 12, 2026. STERIS stock costs EUR 197.65 on October 20, 2026, with USD 21.6 billion value.

Acquisition and earnings calendar

Assenagon increased its STERIS stake by 37.9 percent on October 19, 2026.
STERIS agreed to acquire Xodus Medical for USD 2.10 billion on October 12, 2026.
STERIS stock trades at EUR 197.65 at 1:43 p.m. CEST at Lang & Schwarz on October 20, 2026.

Börsen-Editorialfoto mit Händlern vor Bildschirmen und steigenden Charts im Gesundheitssektor — Steris plc IE00BFY8C754 wird redaktionell am Börsenparkett der NYSE mit steigenden Healthcare-Sektor-Charts abgebildet, Illustration mit AI erstellt.

STERIS plc (ISIN IE00BFY8C754) was trading at EUR 197.65 at Lang & Schwarz on October 20, 2026 at 1:43 p.m. CEST, while its market capitalization stood at USD 21.6 billion as of October 19, 2026. According to MarketBeat on October 19, 2026, Assenagon Asset Management increased its STERIS stake by 37.9 percent to 105,373 shares.

Three dates shape the story

On August 5, 2026, STERIS reported adjusted earnings per share of USD 2.59 and revenue of USD 1.49 billion for fiscal first quarter 2027, with revenue up 7.30 percent year over year, according to MarketBeat. On October 12, 2026, the company announced a USD 2.10 billion agreement to acquire Xodus Medical. On October 19, 2026, Assenagon reported a 37.9 percent increase in its third-quarter holding.

What does Xodus add?

The acquisition expands STERIS's operating-room consumables portfolio. The official STERIS release dated October 12, 2026 projected Xodus revenue of USD 245.00 million and adjusted earnings before interest and taxes of USD 135.00 million for calendar year 2026. The deal is expected to close by December 31, 2026, subject to regulatory approvals, and is expected to be financed primarily with debt.

Reuters reported on October 12, 2026, that Stephens analyst Steven Etoch called the transaction a logical addition to STERIS's healthcare business. Reuters also reported that the company expects USD 300.00 million in cash tax benefits on a net-present-value basis, reducing the effective purchase price to USD 1.80 billion.

When are the next results?

STERIS is scheduled to report fiscal second-quarter 2027 results on November 4, 2026, after the market closes, with a conference call scheduled for November 5, 2026 at 9:00 a.m. ET, according to MarketBeat. The consensus estimate is USD 2.68 in earnings per share on USD 1.56 billion in revenue, compared with USD 2.47 and USD 1.46 billion in the year-earlier quarter.

Stock price and valuation

STERIS's primary listing is on the NYSE under ticker STE. Its last available US-market quote was USD 221.97 on October 19, 2026 at 4:00 p.m. ET, while the 52-week range was USD 195.14 to USD 269.44. The euro quotation puts the acquisition, projected Xodus contribution and upcoming earnings date into one market view.

The stock was trading at EUR 197.65 at Lang & Schwarz on October 20, 2026 at 1:43 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Steris plc stock.